Juventas Lands ￥400 Million Series C Funding

(VCBeat) July. 12, 2021 -- Juventas Cell Therapy Ltd. ("Juventas") today announced the closing of a Series C financing of over 400 million RMB. This round of financing was jointly led by CICC Capital's fund and Oceanpine Healthcare Fund, while Delian Capital and existing investors Jiadao Private Capital, Redhill Capital, Tianjin Venture Capital, Dalton Venture, and Xiangrong Capital also participated. 

The funds will be used for the rapid commercialization and international research and development of Juventas' proprietary CAR-T product -- CNCT19 in China, and the global layout of innovative drug research and development driven by CAR technology platform, iPSCs technology platform, gene-editing technology platform, etc. Therefore the indications of Juventas' products can serve as autologous and universal immune cell therapy for hematologic tumors, solid tumors, etc.

Founded in June 2018, Juventas is a biomedical enterprise focusing on the R&D and commercialization of innovative drugs such as immune cell therapy, which has in-depth cooperation with national first-class institutes and clinical research centers and is committed to building a leading platform for clinical transformation and commercialization of cell therapy, accelerating cell therapy innovation, clinical application and industrialization. 

Juventas creates safe, efficient and accessible immune cell therapy products for patients through strict product production and quality systems. CNCT19, the first product with Chinese independent intellectual property rights, has obtained two new drug clinical trial licenses from the National Medical Products Administration (NMPA), and is used to treat relapsed or refractory acute lymphoblastic leukemia and relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

Meanwhile, Juventas continues to build highly scalable and competitive innovation pipelines, covering hematologic tumor pipelines, solid tumor pipelines and forward-looking general platform pipelines.

CICC Capital is a wholly-owned subsidiary of China's first joint venture investment bank, China International Capital Corporation Limited (CICC). As the private equity investment fund under CICC, CICC Capital provides private equity investment fund services, including making private investment development strategy, promoting business, allocating resources and managing the risk.

With a total AUM of nearly 300 billion yuan, CICC Capital has become one of the largest private equity funds in China.

Oceanpine Healthcare Fund is a healthcare venture fund that aims to connect innovation in the US to the Chinese consumer base, and primarily invests in Chinese and US firms with core technologies and proprietary R&D capabilities. They bridge a supply and demand gap exacerbated by limited R&D in China.